Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest UCB Stories

2010-01-12 12:11:00

February 25-26 Forum to Bring Together Innovators, Clinicians and Investors MIDDLEBURG, Va., Jan. 12 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP), a non-profit organization dedicated to advancing new therapies for people living with epilepsy, announces the Epilepsy Pipeline Update 2010 conference, an in-depth, 2-day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco. The conference will feature a line up of leading innovators, clinical...

2010-01-12 07:00:00

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim's extended-release formulation of pramipexole (pramipexole ER), which launched late last year in Europe and is expected to launch this year in the United States, will garner peak year sales of $250 to $500 million in the world's major pharmaceutical markets. The Pharmacor finding from the topic...

2009-12-14 01:00:00

BRUSSELS, December 14 /PRNewswire-FirstCall/ -- - Results From a Survey Conducted by UCB Assessing the Lifestyles of Women With Rheumatoid Arthritis in Seven Major Industrialized Countries - A third of women living with rheumatoid arthritis say their disease impacts their enjoyment of the festive season - Women living with rheumatoid arthritis find shopping for gifts, preparing holiday food, writing cards and wrapping presents most difficult to do -...

2009-12-07 05:40:00

ATLANTA, Dec. 7 /PRNewswire-FirstCall/ -- UCB today announced new findings on its antiepileptic drug (AED) Vimpat® that offer additional clinical evidence supporting the use of this AED as adjunctive therapy in adult patients with partial-onset seizures. Results of presented research demonstrate sustained efficacy in adult patients taking Vimpat® for up to three years, and a consistent long-term tolerability profile. A separate study reports that...

2009-11-03 08:05:00

ATLANTA, Nov. 3 /PRNewswire/ -- UCB, an active participant in the epilepsy community for more than a decade, is proudly launching a variety of patient-centered initiatives in honor of Epilepsy Awareness Month in November. These programs are the culmination of years of experience in the epilepsy community and seek to empower patients, improve epilepsy care, and raise awareness about the condition. "At UCB, our goal has always been to make a meaningful and lasting difference in the epilepsy...

2009-10-26 10:00:00

SAN DIEGO, Oct. 26 /PRNewswire/ -- According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study. These...

2009-10-26 10:00:00

SAN DIEGO, Oct. 26 /PRNewswire/ -- New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years. In a separate analysis, CIMZIA significantly improved...

2009-10-21 08:00:00

ATLANTA, Oct. 21 /PRNewswire/ -- UCB today announced the 31 recipients of the fourth annual UCB Crohn's Scholarship, awarded to outstanding students of all ages who are living beyond the boundaries of Crohn's disease. To date, the company has granted more than $1 million to individuals pursuing their educational dreams. The 2009 winners are a stellar group of men and women who excel in school, sports, volunteerism and activism despite living with Crohn's disease, a debilitating, chronic...

2009-10-09 23:01:00

PHILADELPHIA, October 10 /PRNewswire-FirstCall/ -- For U.S. Media Only - U.S. women living with rheumatoid arthritis demand more 'good days' - 68 percent of women living with rheumatoid arthritis look for new pain relief therapies to help them cope - Almost 60 percent of women in the U.S. living with rheumatoid arthritis find intimate relations painful - Rheumatoid arthritis played a role in 25 percent of divorces amongst women with the disease A new survey...

2009-09-02 05:00:00

SANTA MONICA, Calif., Sept. 2 /PRNewswire/ -- MTV has tapped hip-hop's newest challenger, Wale and the legendary go-go band UCB as the official house band for the 2009 VMAs, providing the night's soundtrack for the hottest music awards show this year. Not only will Wale perform his new hit single "World Tour," but he will also collaborate with artists including The All-American Rejects, Pitbull and 3OH!3 while putting his own unique spin on some of the biggest songs of the year. "This...